Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10 −9 , odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10 −10 , OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10 −8 , OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10 −11 , OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10 −10 , OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10 −9 , OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10 −10 , OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10 −10 , OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10 −9 , OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10 −8 , OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10 −10 , OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10 −11 , OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10 −9 , OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.
Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10 −9 , odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10 −10 , OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10 −8 , OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10 −11 , OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10 −10 , OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10 −9 , OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10 −10 , OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10 −10 , OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10 −9 , OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10 −8 , OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10 −10 , OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10 −11 , OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10 −9 , OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.
Glioma accounts for around 27% of all primary brain tumors and is responsible for approximately 13,000 cancer-related deaths in the United States each year 1, 2 . Gliomas can be broadly classified into GBM and lower-grade non-GBM tumors 3 . Gliomas typically have a poor prognosis irrespective of medical care, with the most common form, GBM, having a five-year survival rate of only 5% (ref. 4) .
So far, no environmental exposures have been robustly linked to the risk of developing glioma, except for moderate to high doses of ionizing radiation, which accounts for a small proportion of cases 5 . Evidence for an inherited predisposition to glioma is provided by a number of rare inherited cancer syndromes, such as Turcot's and Li-Fraumeni syndromes, as well as neurofibromatosis. Even collectively, however, these account for little of the twofold familial risk of glioma 6 . Our understanding of the heritability of glioma has been transformed by recent GWAS, which have identified single-nucleotide polymorphisms (SNPs) at 13 loci influencing risk [7] [8] [9] [10] [11] [12] [13] [14] .
Previous individual studies have had limited statistical power for the additional discovery of new glioma risk loci 15 . Therefore, to gain more comprehensive insight into glioma etiology, we performed a meta-analysis of previously published GWAS and two new GWAS, which allowed us to identify 13 new risk loci for glioma.
We analyzed GWAS SNP data that passed quality control for 12,496 cases (6, 191 classified as GBM and 5,819 classified as non-GBM tumors) and 18, 190 controls from eight studies with individuals of European ancestry, a new GWAS of 4,572 cases and 3,286 controls performed by the Glioma International Case Control Consortium (GICC) (Supplementary Table 1) , a new GWAS of 1,591 cases and 804 controls from the University of California, San Francisco (UCSF)-Mayo, Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors l e t t e r s and six previously reported GWAS 9,10,13 totaling 6,405 cases and 14,100 controls (Supplementary Table 2 ). To increase genomic resolution, we imputed >10 million SNPs. Quantile-quantile (Q-Q) plots for SNPs with a minor allele frequency (MAF) >1% after imputation did not show evidence of substantive overdispersion (λ = 1.02-1.10, λ 90 = 1.02-1.05; Supplementary Fig. 1 ). We derived joint ORs and 95% confidence intervals (CIs) under a fixed-effects model for each SNP with MAF >1% and associated per-allele principal component (PCA) corrected P-values for all glioma, GBM and non-GBM cases versus those for the controls (Fig. 1) .
In the combined meta-analysis, among previously published glioma risk SNPs, those for all glioma at 17p13.1 (TP53), for GBM at 5p15.33 (TERT), 7p11.2 (EGFR), 9p21.3 (CDKN2B-AS1) and 20q13.33 (RTEL1), and for non-GBM tumors at 8q24.21 (CCDC26), 11q23.2, 11q23.3 (PHLDB1) and 15q24.2 (ETFA) showed even greater evidence for association ( Supplementary Fig. 2 and Supplementary  Table 3 ). SNPs at 10q25.2 and 12q12.1 for non-GBM tumors retained genome-wide significance (i.e., P < 5.0 × 10 −8 ). Associations at the previously reported 3q26.2 (near TERC) 11 and 12q23.33 (POLR3B) 10 loci for GBM did not retain statistical significance (P values for the most associated SNPs are 2.68 × 10 −5 and 1.60 × 10 −5 , respectively; Supplementary Table 3) .
In addition to previously reported loci, we identified genomewide significant associations marking new risk loci ( Table 1 , Supplementary Fig. 3 and Supplementary Data 1) for GBM at 1p31.3 (rs12752552; P = 2.04 × 10 −9 ), 11q14.1 (rs11233250; P = 9.95 × 10 −10 ), 16p13.3 (rs2562152; P = 1.93 × 10 −8 ), 16q12.1 (rs10852606; P = 1.29 × 10 −11 ) and 22q13.1 (rs2235573; P = 1.76 × 10 −10 ) and for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10 −9 ), 1q44 (rs12076373; P = 2.63 × 10 −10 ), 2q33.3 (rs7572263; P = 2.18 × 10 −10 ), 3p14.1 (rs11706832; P = 7.66 × 10 −9 ), 10q24.33 (rs11598018; P = 3.39 × 10 −8 ), 11q21 (rs7107785; P = 3.87 × 10 −10 ), 14q12 (rs10131032; P = 5.07 × 10 −11 ) and 16p13.3 (rs3751667; P = 2.61 × 10 −9 ). Conditional analysis confirmed the existence of two independent association signals at 7p11.2 (EGFR) as previously reported 7 but did not provide evidence for additional signals at any of the other established identified risk loci or at the 13 newly identified loci. Case-only analyses confirmed the specificity of 11q14.1, 16p13.3 and 22q13.1 associations for GBM and of 1q44, 2q33.3, 3p14.1, 11q21 and 14q12 associations for non-GBM tumors ( Fig. 2 and Supplementary Table 4) . Collectively, our findings provide strong evidence for specific associations for the different glioma subtypes, consistent with their previously described distinctive molecular profiles, presumably resulting from different etiological pathways.
Across the new and known risk loci, we found a significant enrichment of overlap with enhancers in H9-Derived neuronal progenitor cells (P = 8.2 × 10 −5 ; Supplementary Data 2). These observations support the assertion that the loci identified in the GWAS influence glioma risk through effects on neural cis regulatory networks and that they are strongly involved in transcriptional initiation and enhancement. To gain further insight into the biological basis for associations at the 13 new risk loci, we performed an expression quantitative trait loci (eQTL) analysis using RNA-seq data on ten regions of normal human brain from up to 103 individuals from the Genotype-Tissue Expression (GTEx) project 16 and blood eQTL data on 5,311 individuals from Westra et al. 17 . We used summary-level mendelian randomization (SMR) 18 analysis to test for a concordance between signals from GWAS and cis eQTL for genes within 1 Mb of the sentinel and correlated SNPs (r 2 > 0.8) at each locus (Supplementary Data 3) and derived b XY statistics, which estimate the effect of gene expression on glioma risk. Additionally, for each of the risk SNPs at the 13 new loci (as well as the correlated variants), we examined published data 19, 20 and made use of the online resources HaploRegv4, RegulomeDB and SeattleSeq for evidence of functional effects (Supplementary Table 5 ).
At 16q12.1, the GBM association signal was significantly associated with HEATR3 expression in nine of ten regions of the brain (P SMR = 3.38 × 10 −6 to 6.55 × 10 −10 ; b XY = 0.14-0.24; Supplementary Fig. 4 and Supplementary Data 3). The risk allele 'C' of rs10852606 that was associated with reduced HEATR3 expression was consistent with differential expression of HEATR3 being the functional basis of the 16q12.1 association. The observation that variation at 16q12.1 is associated with risk of testicular 21 (rs8046148; pairwise r 2 and D′ with rs10852606 of 0.67 and 1.0, respectively) and esophageal 22 (rs4785204; pairwise r 2 and D′ with rs10852606 of 0.16 and 1.0, respectively) cancer suggests that the locus has pleiotropic effects on tumor risk, which are compatible with generic effects as shown by the observation of a HEATR3 eQTL signal in blood (P SMR = 5.84 × 10 −11 ; b XY = 0.30).
Similarly, significant associations between gene expression and glioma risk were observed at the GBM loci 1p31.3 (JAK1, brain cortex and cerebellar hemisphere), 16p13.3 (POLR3K, whole blood) and 22q13.1 (CTA-228A9.3, brain cerebellum; PICK1, brain hippocampus) ( Supplementary Fig. 4 and Supplementary Data 3). The non-GBM association at 1q32.1 marked by rs4252707 (Supplementary Fig. 3 ) l e t t e r s maps to intron 8 of the gene encoding MDM4, a p53-binding protein.
The SNP rs4252707 is in strong linkage disequilibrium (LD) with rs12031912 and rs12028476 (r 2 = 0.92), both of which map to the MDM4 promoter. Although no significant eQTL was shown in any brain tissue, an association with MDM4 was seen in blood (P SMR = 4.74 × 10 −6 ; b XY = 0.31; Supplementary Fig. 4 and Supplementary Data 3). Overexpression of MDM4 is a feature in glioma tumors containing wild-type TP53 and no amplification of the MDM2 gene, consistent with MDM4 amplification being a mechanism by which the p53-dependent growth control is inactivated 23 . The 1q44 association with non-GBM that is marked by rs12076373 maps to intron 8 of AKT3, whose encoded product is one of the major downstream effectors of phosphatidylinositol 3-kinase (PI3K) and is highly expressed during active neurogenesis, with haploinsufficiency causing postnatal microcephaly and agenesis of the corpus callosum 24 . Notably, AKT3 is hyper-expressed in glioma, thus having a role in tumor viability by activating DNA repair 25 . Although rs12076373 does not map to a regulatory element, the correlated SNPs rs12124113 (r 2 = 0.94) and rs59953491 (r 2 = 0.90) locate within an enhancer element in brain cells and tissues, including H9-derived neuronal progenitor cultured cells, cortex-derived primary cultured neurospheres and NH-A astrocytes.
The 3p14.1 association with non-GBM that is marked by rs11706832 localizes to intron 2 of LRIG1. Although we did not identify an eQTL in this gene, LRIG1 is highly expressed in the brain and is a pannegative regulator of the epidermal growth factor receptor (EGFR) signaling pathway, which inhibits hypoxia-induced vasculogenic mimicry via EGFR-PI3K-AKT pathway suppression and epithelialto-mesenchymal transition 26 . Reduced LRIG1 expression is linked to tumor aggressiveness, temozolomide resistance and radioresistance 27, 28 . We have previously shown an association for glioma at EGFR (7p11.2) 7 , which is well established to be pivotal in both the initiation of primary GBM and the progression of lower-grade glioma to grade IV. Although speculative, our new findings now suggest a more extensive pathway involving variation at LRIG1 and AKT3.
Of particular interest is rs7572263, which maps to 2q33.3, localizes within intron 3 of C2orf80 and is 50 kb telomeric to IDH1. Mutation Genomes project. The INFO column indicates the average imputation info score across all studies, with a score of 1 indicating that the SNP is directly genotyped in all studies. CI, confidence interval. l e t t e r s of IDH1 is a driver for gliomagenesis 29, 30 and is responsible for the CpG island methylator (G-CIMP) phenotype 31, 32 . Mutations in IDH1 predominate in non-GBM glioma 33, 34 ; therefore, the association at 2q33.3 is plausible as a basis for susceptibility to non-GBM glioma. In the absence of convincing eQTL or other functional support, this does not preclude C2orf80 or another gene mapping to the region of LD as being the functional basis for the 2q33.3 association.
The maintenance of telomeres is central to cell immortalization, and it has a central role in gliomagenesis 35 . We have previously shown that the risk of GBM is strongly linked to genetic variation in the telomere-related genes TERT (5p15.33) and RTEL1 (20q13.33), and possibly also TERC (3q26.2) 8,9,11 . The 10q24.33 association with non-GBM that is marked by rs11598018 lies intronic to OBFC1, which functions in a telomere-associated complex that protects telomeres independently of POT1 (ref. 36) . The CST complex, whose components are encoded by OBFC1, CTC1, and TEN1, competes with shelterin for telomeric-DNA-inhibiting telomerase-based telomere extension 37 . The significant association between the risk of non-GBM tumors and OBFC1 variation is particularly of note in light of our recent exome-sequencing report demonstrating that rare germline loss-of-function mutations in genes that encode components of the shelterin complex are a cause of familial oligodendroglioma 38 . The glioma risk alleles at TERT, TERC and OBFC1 are associated with increased leukocyte telomere length, thereby supporting a relationship between genotype and biology (Supplementary Table 6 ) 35, 39, 40 . However, the RTEL1 locus is not consistent with such a postulate, and recent data that have not shown a relationship between mutations in the TERT promoter and telomere length in glioma 41 raise the possibility of a role for extratelomeric effects.
The deregulation of pathways involved in telomere length and EGFR signaling are thus consistent with glioma risk being governed by pathways that are important in the longevity of glial cells, and they substantiate early observations that genetic susceptibility to GBM and non-GBM tumors is highly distinct, presumably reflecting different etiologies between GBM and non-GBM tumors (Fig. 2) .
The other associations we identified mark genes with varying degrees of plausibility for having a role in glioma oncogenesis. The GBM association at 16p13.33 marked by rs2562152 localizes 3 kb telomeric to MPG, which encodes a N-methylpurine DNA glycosylase whose expression is linked to temozolomide resistance in glioma 42 . Although attractive as a candidate, the only genes for which there was found to be a significant association between expression and glioma risk were POLR3K and C16ORF33 in blood ( Supplementary Fig. 4 and Supplementary Data 3) . At 1p31.3, only JAK1 provided convincing evidence for a significant eQTL with glioma risk SNPs in brain tissue. The strongest association was shown in the cortex (P SMR = 1.61 × 10 −6 ; b XY = 0.22; Supplementary Fig. 4 and Supplementary  Data 3) , with the risk allele 'T' of rs12752552 showing increased JAK1 expression. The cis-eQTL signal for JAK1 in the cortex maps from 65.3 Mb to 65.35 Mb and shows a consistent direction of effect with the glioma-associated SNPs. JAK1-STAT6 signaling is increasingly being recognized to be relevant in glioma progression 43 . Hence, although JAK1 remains an attractive candidate mechanistic basis for the glioma association at 1p31.3, we cannot exclude the possibility that the cluster of SNPs between 65.3 Mb and 65.35 Mb contains the true causal variant. In the absence of functional data, potential target genes for associations at 11q14.1 (GBM), 16p13.3 (non-GBM), 11q21 (non-GBM) and 14q12 (non-GBM) remain to be elucidated.
In conclusion, we have performed the largest glioma GWAS to date and have identified 13 new glioma risk loci, thereby providing further evidence for a polygenic basis of genetic susceptibility to glioma.
Histological classification of glioma is, in part, being superseded by molecular profiling 34, 44 ; hence, it is important to understand the biology behind these risk variants in the context of molecularly defined glioma subtypes. Currently identified risk SNPs for glioma account for, at best, ~27% and ~37% of the familial risk of GBM and non-GBM tumors, respectively (Supplementary Table 7) . Therefore, further GWAS-based analyses in concert with functional analyses should lead to additional insights into the biology and etiological basis of the different glioma histologies. Notably, such information can inform gene discovery initiatives and thus have a measurable effect on the successful development of new therapeutic agents.
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